Literature DB >> 26106001

Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma.

Noriaki Yoshida1, Yoshitaka Imaizumi, Atae Utsunomiya, Hiroaki Miyoshi, Fumiko Arakawa, Kunihiro Tsukasaki, Koichi Ohshima, Masao Seto.   

Abstract

Adult T-cell leukemia/lymphoma (ATLL) is a T-cell neoplasm caused by human T-cell leukemia virus type I (HTLV-I). ATLL is classified into four clinical subtypes based on the clinical manifestation: acute, lymphoma, chronic and smoldering. Approximately half of chronic type ATLL cases progressed to the acute type. We previously demonstrated that genomic alterations related to the cell cycle de-regulation such as CDKN2A and immune escape such as CD58 alteration can serve as predictive biomarkers for acute transformation of the chronic type. Although alteration of TP53, which is known to be a major regulator of cell cycle, has been identified in several types of cancers including acute type ATLL, no copy number alteration of TP53 was found in the chronic type by array comparative genomic hybridization. In the present study, mutation of TP53 was further analyzed by sequencing for these cases as well as HTLV-I carriers with oligo-clonality. However, no TP53 mutation was identified. These results suggested that TP53 mutation plays a role for the later stage of ATLL development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26106001     DOI: 10.3960/jslrt.55.13

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  2 in total

1.  Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.

Authors:  Yuma Sakamoto; Takashi Ishida; Ayako Masaki; Takayuki Murase; Morishige Takeshita; Reiji Muto; Hiromi Iwasaki; Asahi Ito; Shigeru Kusumoto; Nobuaki Nakano; Masahito Tokunaga; Kentaro Yonekura; Yukie Tashiro; Shinsuke Iida; Atae Utsunomiya; Ryuzo Ueda; Hiroshi Inagaki
Journal:  Br J Haematol       Date:  2021-08-17       Impact factor: 8.615

Review 2.  Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors.

Authors:  Robert Harrod
Journal:  Retrovirology       Date:  2019-09-06       Impact factor: 4.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.